Keratosis palmoplantaris striata 2
diseaseOn this page
Also known as DSP striate palmoplantar keratodermakeratosis palmoplantaris striata IIkeratosis palmoplantaris striata type 2PPKS2striate palmoplantar keratoderma caused by mutation in DSP
Summary
Keratosis palmoplantaris striata 2 (MONDO:0013034) is a disease caused by DSP (GenCC Definitive), with 2 cohort genes.
At a glance
- Causal gene: DSP (GenCC Definitive)
- Cohort genes: 2
- ClinVar variants: 287
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | keratosis palmoplantaris striata 2 |
| Mondo ID | MONDO:0013034 |
| MeSH | C565102 |
| OMIM | 612908 |
| DOID | DOID:0081109 |
| UMLS | C1852127 |
| MedGen | 343725 |
| GARD | 0015590 |
| Is cancer (heuristic) | no |
Also known as: DSP striate palmoplantar keratoderma · keratosis palmoplantaris striata II · keratosis palmoplantaris striata type 2 · PPKS2 · striate palmoplantar keratoderma caused by mutation in DSP
Data availability: 287 ClinVar variants · 3 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › keratosis › palmoplantar keratosis › hereditary palmoplantar keratoderma › focal palmoplantar keratoderma › striate palmoplantar keratoderma › keratosis palmoplantaris striata 2
Related subtypes (1): keratosis palmoplantaris striata 3
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
287 retrieved; paginated sample, class counts are floors:
153 conflicting classifications of pathogenicity, 72 uncertain significance, 19 likely benign, 13 benign/likely benign, 11 pathogenic/likely pathogenic, 10 likely pathogenic, 7 benign, 2 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 16836 | NM_004415.4(DSP):c.991C>T (p.Gln331Ter) | DSP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 16844 | NM_004415.4(DSP):c.6091_6092del (p.Leu2031fs) | DSP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 178282 | NM_004415.4(DSP):c.939+1G>A | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 199884 | NM_004415.4(DSP):c.4198C>T (p.Arg1400Ter) | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 199916 | NM_004415.4(DSP):c.928dup (p.Glu310fs) | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 405232 | NM_004415.4(DSP):c.5680_5683del (p.Ser1894fs) | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 432027 | NM_004415.4(DSP):c.7641C>G (p.Tyr2547Ter) | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 44946 | NM_004415.4(DSP):c.699G>A (p.Trp233Ter) | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 452266 | NM_004415.4(DSP):c.4882_4886delinsTTCT (p.Arg1628fs) | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 489339 | NM_004415.4(DSP):c.3241G>T (p.Glu1081Ter) | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 570298 | NM_004415.4(DSP):c.4037_4041del (p.Asn1346fs) | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 578291 | NM_004415.4(DSP):c.6504_6507del (p.Ser2168fs) | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 620416 | NM_004415.4(DSP):c.7066A>T (p.Lys2356Ter) | DSP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1710286 | NM_004415.4(DSP):c.1782C>A (p.Ser594Arg) | DSP | Likely pathogenic | no assertion criteria provided |
| 228254 | NM_004415.4(DSP):c.3507C>A (p.Tyr1169Ter) | DSP | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3382021 | NM_004415.4(DSP):c.4407_4423del (p.Asp1470fs) | DSP | Likely pathogenic | criteria provided, single submitter |
| 3382672 | NM_004415.4(DSP):c.2241del (p.Phe747fs) | DSP | Likely pathogenic | criteria provided, single submitter |
| 3382799 | NM_004415.4(DSP):c.2359del (p.Tyr787fs) | DSP | Likely pathogenic | criteria provided, single submitter |
| 3779588 | NM_004415.4(DSP):c.418A>T (p.Lys140Ter) | DSP | Likely pathogenic | criteria provided, single submitter |
| 4294461 | NM_004415.4(DSP):c.4042del (p.Glu1347_Leu1348insTer) | DSP | Likely pathogenic | criteria provided, single submitter |
| 636850 | NM_004415.4(DSP):c.4954del (p.Glu1652fs) | DSP | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 930487 | NM_004415.4(DSP):c.621G>A (p.Trp207Ter) | DSP | Likely pathogenic | criteria provided, single submitter |
| 1066406 | NM_004415.4(DSP):c.170+1G>A | DSP-AS1 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1006139 | NM_004415.4(DSP):c.1279A>G (p.Lys427Glu) | DSP | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1018875 | NM_004415.4(DSP):c.8172G>T (p.Gln2724His) | DSP | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1041857 | NM_004415.4(DSP):c.2959T>A (p.Ser987Thr) | DSP | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1060668 | NM_004415.4(DSP):c.4558A>G (p.Ser1520Gly) | DSP | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1060837 | NM_004415.4(DSP):c.8566T>A (p.Ser2856Thr) | DSP | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1172188 | NM_004415.4(DSP):c.4901G>T (p.Arg1634Leu) | DSP | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1339298 | NM_004415.4(DSP):c.2962C>T (p.Pro988Ser) | DSP | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 26 · Orphanet: 11 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| DSP | Definitive | Autosomal dominant | keratosis palmoplantaris striata 2 | 26 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| DSP | Orphanet:154 | Familial isolated dilated cardiomyopathy |
| DSP | Orphanet:158687 | Lethal acantholytic erosive disorder |
| DSP | Orphanet:2032 | Idiopathic pulmonary fibrosis |
| DSP | Orphanet:293165 | Skin fragility-woolly hair-palmoplantar keratoderma syndrome |
| DSP | Orphanet:293888 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant |
| DSP | Orphanet:293899 | Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant |
| DSP | Orphanet:293910 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant |
| DSP | Orphanet:369992 | Severe dermatitis-multiple allergies-metabolic wasting syndrome |
| DSP | Orphanet:476096 | Erythrokeratodermia-cardiomyopathy syndrome |
| DSP | Orphanet:50942 | Striate palmoplantar keratoderma |
| DSP | Orphanet:65282 | Carvajal syndrome |
Cohort genes → proteins
2 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 2 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| DSP | HGNC:3052 | ENSG00000096696 | P15924 | Desmoplakin | gencc,clinvar |
| DSP-AS1 | HGNC:56039 | ENSG00000261189 | DSP antisense RNA 1 | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| DSP | Desmoplakin | A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion. |
Protein-family classification
Druggable: 0 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Scaffold/PPI | 1 | 8.6× | 0.225 |
| Other/Unknown | 1 | 0.9× | 0.805 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| DSP | Scaffold/PPI | no | Plectin_repeat, SH3_domain, Spectrin/alpha-actinin | |
| DSP-AS1 | Other/Unknown | no |
Expression context
Cohort genes with no expression data: 0.
2 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 2 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| hair follicle | 1 |
| skin of hip | 1 |
| upper leg skin | 1 |
| apex of heart | 1 |
| male germ line stem cell (sensu Vertebrata) in testis | 1 |
| right atrium auricular region | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| DSP | 253 | ubiquitous | marker | skin of hip, upper leg skin, hair follicle |
| DSP-AS1 | 162 | marker | male germ line stem cell (sensu Vertebrata) in testis, apex of heart, right atrium auricular region |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| DSP | 2,897 |
| DSP-AS1 | 0 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 1
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| DSP | P15924 | 4 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 6. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Apoptotic cleavage of cell adhesion proteins | 1 | 1038.2× | 0.006 | DSP |
| RND1 GTPase cycle | 1 | 265.6× | 0.008 | DSP |
| RND3 GTPase cycle | 1 | 259.6× | 0.008 | DSP |
| Formation of the cornified envelope | 1 | 87.8× | 0.017 | DSP |
| Keratinization | 1 | 55.7× | 0.022 | DSP |
| Neutrophil degranulation | 1 | 23.1× | 0.043 | DSP |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| ventricular compact myocardium morphogenesis | 1 | 2407.4× | 0.002 | DSP |
| bundle of His cell-Purkinje myocyte adhesion involved in cell communication | 1 | 2407.4× | 0.002 | DSP |
| desmosome organization | 1 | 2106.5× | 0.002 | DSP |
| protein localization to cell-cell junction | 1 | 1872.4× | 0.002 | DSP |
| peptide cross-linking | 1 | 1404.3× | 0.002 | DSP |
| regulation of ventricular cardiac muscle cell action potential | 1 | 1404.3× | 0.002 | DSP |
| epithelial cell-cell adhesion | 1 | 1203.7× | 0.002 | DSP |
| intermediate filament cytoskeleton organization | 1 | 936.2× | 0.002 | DSP |
| adherens junction organization | 1 | 510.7× | 0.003 | DSP |
| skin development | 1 | 443.5× | 0.004 | DSP |
| regulation of heart rate by cardiac conduction | 1 | 374.5× | 0.004 | DSP |
| keratinocyte differentiation | 1 | 247.8× | 0.005 | DSP |
| intermediate filament organization | 1 | 240.7× | 0.005 | DSP |
| wound healing | 1 | 227.7× | 0.005 | DSP |
| epidermis development | 1 | 210.7× | 0.005 | DSP |
| cell-cell adhesion | 1 | 101.5× | 0.010 | DSP |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2
Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| DSP | 0 | 0 |
| DSP-AS1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| DSP | 2 | Binding:2 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 2 | DSP, DSP-AS1 |
Undrugged target profiles
2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| DSP | 2 | — |
| DSP-AS1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.